Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved ...

With an estimated 32,000 Canadians diagnosed with lung cancer in 2024, Merck Canada aims to promote lung health with a new self-assessment tool. KIRKLAND, Quebec--(BUSINESS WIRE)--Today on World ...

Merck, known as MSD outside the U.S. and Canada, is restructuring its Human Health organization and appointing three new leaders.

Royal Bank Of Canada initiated coverage on Merck & Co., Inc.with an outperform rating The company reported quarterly revenue ...

This campaign aims to empower Canadians with resources to help recognize and prevent melanoma KIRKLAND, QC, June 19, 2024 /CNW/ - This summer, Merck Canada is empowering Canadians with tools and ...

Merck Canada announced this month a deal with Mihealth to promote its PHR offering to Canadian doctors. According to Mihealth, which has an exclusive license to Diversinet's MobiSecure platform in ...

(RTTNews) - Merck & Co., Inc. (MRK), Thursday announced that ENFLONSIA, also known as clesrovimab, has been approved by Health Canada for the prevention of respiratory syncytial virus lower ...

In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, in PD-L1+ ...

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...

Merck & Co. (MRK), known as MSD outside the United States and Canada, on Thursday reported positive second-season results from the Phase 3 SMART trial evaluating ENFLONSIA (clesrovimab) in infants and ...